Briganti, A., de Almeida Luz, M., Suzuki, H., Murphy, D., Pieczonka, C., Yu, E. Y., … Armstrong, A. J. (2025). 2458P Real-world experience with darolutamide in 799 patients with nonmetastatic castration-resistant prostate cancer (nmCRPC): Prespecified interim analysis of the DAROL prospective observational study. In Annals of Oncology (Vol. 36, pp. S1334–S1335). Elsevier BV. https://doi.org/10.1016/j.annonc.2025.08.3073

Briganti, A., M. de Almeida Luz, H. Suzuki, D. Murphy, C. Pieczonka, E. Y. Yu, P. Adorjan, M. Ghadessi, F. Verholen, and A. J. Armstrong. “2458P Real-world experience with darolutamide in 799 patients with nonmetastatic castration-resistant prostate cancer (nmCRPC): Prespecified interim analysis of the DAROL prospective observational study.” In Annals of Oncology, 36:S1334–35. Elsevier BV, 2025. https://doi.org/10.1016/j.annonc.2025.08.3073.

Briganti A, de Almeida Luz M, Suzuki H, Murphy D, Pieczonka C, Yu EY, et al. 2458P Real-world experience with darolutamide in 799 patients with nonmetastatic castration-resistant prostate cancer (nmCRPC): Prespecified interim analysis of the DAROL prospective observational study. In: Annals of Oncology. Elsevier BV; 2025. p. S1334–5.

Briganti, A., et al. “2458P Real-world experience with darolutamide in 799 patients with nonmetastatic castration-resistant prostate cancer (nmCRPC): Prespecified interim analysis of the DAROL prospective observational study.” Annals of Oncology, vol. 36, Elsevier BV, 2025, pp. S1334–35. Crossref, doi:10.1016/j.annonc.2025.08.3073.

Briganti A, de Almeida Luz M, Suzuki H, Murphy D, Pieczonka C, Yu EY, Adorjan P, Ghadessi M, Verholen F, Armstrong AJ. 2458P Real-world experience with darolutamide in 799 patients with nonmetastatic castration-resistant prostate cancer (nmCRPC): Prespecified interim analysis of the DAROL prospective observational study. Annals of Oncology. Elsevier BV; 2025. p. S1334–S1335.